These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 24071466)
1. Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients. Tomita H; Kadokami T; Momii H; Kawamura N; Yoshida M; Inou T; Fukuizumi Y; Usui M; Funakoshi K; Yamada S; Aomori T; Yamamoto K; Uno T; Ando S; Thromb Res; 2013 Nov; 132(5):537-42. PubMed ID: 24071466 [TBL] [Abstract][Full Text] [Related]
2. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826 [TBL] [Abstract][Full Text] [Related]
3. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention. Hirano T; Kaneko H; Mishina S; Wang F; Morita S J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651 [TBL] [Abstract][Full Text] [Related]
4. Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study. Li Y; Yu J; Kuang Y; Wu C; Yang L; Fang Q; Pei Q; Yang G Curr Med Res Opin; 2020 Sep; 36(9):1433-1439. PubMed ID: 32677855 [TBL] [Abstract][Full Text] [Related]
5. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation. Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319 [TBL] [Abstract][Full Text] [Related]
6. Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD). Nakagita K; Wada K; Mukai Y; Uno T; Nishino R; Matsuda S; Takenaka H; Terakawa N; Oita A; Takada M Eur J Clin Pharmacol; 2018 Jul; 74(7):885-894. PubMed ID: 29781049 [TBL] [Abstract][Full Text] [Related]
7. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and infuential factors-. Okumura K; Komatsu T; Yamashita T; Okuyama Y; Harada M; Konta Y; Hatayama T; Horiuchi D; Tsushima E Circ J; 2011; 75(9):2087-94. PubMed ID: 21737950 [TBL] [Abstract][Full Text] [Related]
8. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up. Wypasek E; Mazur P; Bochenek M; Awsiuk M; Grudzien G; Plicner A; Undas A J Physiol Pharmacol; 2016 Jun; 67(3):385-93. PubMed ID: 27511999 [TBL] [Abstract][Full Text] [Related]
9. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors. Lu Y; Yang J; Zhang H; Yang J Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956 [TBL] [Abstract][Full Text] [Related]
10. Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. Praxedes MFS; Martins MAP; Mourão AOM; Gomes KB; Reis EA; Souza RP; Campos EIF; Ribeiro DD; Rocha MOC Eur J Clin Pharmacol; 2020 Feb; 76(2):199-209. PubMed ID: 31720756 [TBL] [Abstract][Full Text] [Related]
11. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348 [TBL] [Abstract][Full Text] [Related]
12. Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery. Liu Z; Luo F; Zhao J; Chen W; Gao W; Zhou Z Pharmacol Rep; 2024 Apr; 76(2):390-399. PubMed ID: 38457019 [TBL] [Abstract][Full Text] [Related]
13. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients. Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930 [TBL] [Abstract][Full Text] [Related]
14. Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. Liang HF; Du X; Zhou YC; Yang XY; Xia SJ; Dong JZ; Lip GYH; Ma CS Med Sci Monit; 2019 Jun; 25():4691-4698. PubMed ID: 31232394 [TBL] [Abstract][Full Text] [Related]
15. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797 [TBL] [Abstract][Full Text] [Related]
16. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA; J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of warfarin dosing in Chinese adults with nonvalvular atrial fibrillation. Zhu Y; You J; Gu X; Zhu H; Liu J Eur J Clin Pharmacol; 2023 Mar; 79(3):427-435. PubMed ID: 36708395 [TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919 [TBL] [Abstract][Full Text] [Related]
19. Chinese stroke patients with atrial fibrillation used Robert's age-adjusted warfarin loading protocol obtained good INR results within therapeutic range. Luo W; Luo X; Chen S; Li J; Huang X; Rao Y; Xu W Sci Rep; 2023 Oct; 13(1):18230. PubMed ID: 37880296 [TBL] [Abstract][Full Text] [Related]
20. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]